Upcoming annual medical conferences where important clinical data realeases expected
NACF (national Cf meeting) Oct. 19
ACR (national rheumatology meeting) Oct 25
AASLD (national hepatology meeting) Nov 1 through Nov 5
Over the two weeks from Oct 19 through Nov 5 expect new data on the CF RA and hep C drugs in development from Vertex (if not released earlier), and well as announcements of partnership/licensing deals for ongoing development of VX 509 and VX 787. These represent a flurry of data that will likely enhance analyst valuation of VRTX projected growth over the next few years, and likely push the stock higher in price.